Characteristic | n (%) |
---|---|
Patients, n (%) | 3430 (100) |
Gender, n (%) | |
Male | 1993 (58.1) |
Female | 1387 (40.4) |
Mean age, years ± SD (range); n = 3322 | 53.4 ± 10.4 (19.0–89.0) |
Age, n (%) | |
<65 years | 2836 (82.7) |
≥65 years | 486 (14.2) |
Race, n (%) | |
Asian | 1212 (35.3) |
White | 966 (28.2) |
Black | 96 (2.8) |
Other | 970 (28.3) |
Mean BMI, kg/m2 ± SD (range); n = 3214 | 29.9 ± 5.2 (15.1–57.4) |
Mean BP, mm Hg ± SD (range) | |
SBP [n = 3413] | 166.4 ± 16.7 (100.0–260.0) |
DBP [n = 3418] | 99.7 ± 9.9 (55.0–170.0) |
Stages of hypertension, n (%)a | |
Normal | 8 (0.2) |
High normal | 16 (0.5) |
Grade 1 (mild) | 407 (11.9) |
Grade 2 (moderate) | 1620 (47.2) |
Grade 3 (severe) | 1142 (33.3) |
Isolated systolic hypertension | 218 (6.4) |
Duration of hypertension, n (%); n = 3426 | |
Newly diagnosed | 479 (14.0) |
Previously diagnosed | 2947 (85.9) |
<1 year | 434 (14.7) |
1–5 years | 1210 (41.1) |
6–10 years | 692 (23.5) |
>10 years | 554 (18.8) |
Previous antihypertensive therapy, n (%) | |
0 | 421 (12.3) |
1 | 1314 (38.3) |
2 | 1067 (31.1) |
≥3 | 521 (15.2) |
Previous classes of antihypertensive therapy, n (%); n = 2922b | |
ACE inhibitors | 1210 (41.4) |
ARBs | 833 (28.5) |
CCBsc | 348 (11.9) |
β-blockers | 1389 (47.5) |
Thiazide diuretics | 940 (32.2) |
Other | 97 (3.3) |
Smoking history, n (%) | |
Current smoker | 725 (21.1) |
Never | 1940 (56.6) |
Past smoker | 606 (17.7) |